Home › Companies › SYRE

Spyre Therapeutics, Inc.

SYRE Lead: Phase 2 5 Biotech Distilled articles ↓

Immunology Protein

Most recent annual filing: 2026-04-15

Pipeline (12 active programs)

SPY001

Protein Target: α4β7, α4β7 integrin

Ulcerative Colitis Phase 2 subcutaneous Paragon Therapeutics
Crohn's Disease Phase 2 subcutaneous Paragon Therapeutics

SPY002

Protein Target: TL1A

Ulcerative Colitis Phase 2 subcutaneous Paragon Therapeutics
Crohn's Disease Phase 2 subcutaneous

SPY003

Protein Target: IL-23

Ulcerative Colitis Phase 2 subcutaneous Paragon Therapeutics
Crohn's Disease Phase 2 subcutaneous

SPY072

Protein Target: TL1A

Rheumatoid Arthritis Phase 2 subcutaneous Paragon Therapeutics
Psoriatic Arthritis Phase 2 subcutaneous Paragon Therapeutics
Axial Spondyloarthritis Phase 2 subcutaneous Paragon Therapeutics

SPY120

Protein Target: α4β7, TL1A

Ulcerative Colitis Phase 2 subcutaneous

SPY130

Protein Target: α4β7, IL-23

Ulcerative Colitis Phase 2 subcutaneous

SPY230

Protein Target: TL1A, IL-23

Ulcerative Colitis Phase 2 subcutaneous

Biotech Distilled coverage (5)

2026-04-27 UPDATE: Spyre Therapeutics (SYRE) - The Canary Sang 🔒 Paid
2026-04-10 UPDATE: Spyre Therapeutics (SYRE) - The Binary Event is Here – April 13
2026-02-21 UPDATE: Spyre Therapeutics (SYRE) - Q4 Earnings, ECCO Data, & The $500M Shelf 🔒 Paid
2026-01-13 UPDATE: Spyre Therapeutics (SYRE) – Q1 2026 Status Check 🔒 Paid
2025-12-18 Spyre Therapeutics (SYRE): Scientific Due Diligence for Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.